Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Gyre Therapeutics (GYRE) EBIT Margin (2016 - 2025)

Historic EBIT Margin for Gyre Therapeutics (GYRE) over the last 16 years, with Q3 2025 value amounting to 22.66%.

  • Gyre Therapeutics' EBIT Margin rose 60500.0% to 22.66% in Q3 2025 from the same period last year, while for Sep 2025 it was 11.22%, marking a year-over-year increase of 837000.0%. This contributed to the annual value of 15.28% for FY2024, which is 745400.0% up from last year.
  • According to the latest figures from Q3 2025, Gyre Therapeutics' EBIT Margin is 22.66%, which was up 60500.0% from 8.11% recorded in Q2 2025.
  • Gyre Therapeutics' 5-year EBIT Margin high stood at 39.84% for Q3 2023, and its period low was 1851.51% during Q1 2022.
  • For the 5-year period, Gyre Therapeutics' EBIT Margin averaged around 426.11%, with its median value being 8.11% (2025).
  • Its EBIT Margin has fluctuated over the past 5 years, first tumbled by -14985500bps in 2021, then soared by 18782400bps in 2023.
  • Quarter analysis of 5 years shows Gyre Therapeutics' EBIT Margin stood at 832.5% in 2021, then surged by 97bps to 22.13% in 2022, then tumbled by -1425bps to 337.53% in 2023, then soared by 101bps to 2.39% in 2024, then surged by 850bps to 22.66% in 2025.
  • Its last three reported values are 22.66% in Q3 2025, 8.11% for Q2 2025, and 10.3% during Q1 2025.